# Method for Inactivating and Fixing Unstained Smear Preparations of *Mycobacterium tuberculosis* for Improved Laboratory Safety

Pamela Chedore,<sup>1</sup>\* Cecelia Th'ng,<sup>1</sup> Dennis H. Nolan,<sup>2</sup> George M. Churchwell,<sup>2</sup> David E. Sieffert,<sup>2</sup> Yvonne M. Hale, $^2$  and Frances Jamieson<sup>1</sup>

*Laboratories Branch, Ontario Ministry of Health and Long-Term Care, Toronto, Ontario, Canada,*<sup>1</sup> *and Florida Department of Health, Bureau of Laboratories, Jacksonville, Florida*<sup>2</sup>

Received 3 June 2002/Returned for modification 9 July 2002/Accepted 14 August 2002

**The inactivation of smears that contain** *Mycobacterium tuberculosis* **for microscopy before removal of the material from a biosafety cabinet is an important safety factor in preventing the potential transmission of tuberculosis to laboratory workers. The fixing and inactivating properties of heat flaming, 70% ethanol, and 1, 3, and 5% phenol in ethanol for smears containing** *M***.** *tuberculosis* **were investigated. Heat flaming failed to inactivate the smear material, whereas 5% phenol in ethanol successfully fixed and inactivated all smears containing** *M***.** *tuberculosis* **both from concentrated sputum samples and from culture material.**

The potential hazard of laboratory work with *Mycobacterium tuberculosis* is well recognized. There are numerous records of laboratory-acquired tuberculosis (TB) infections, with aerosols and skin punctures being the most common reported routes of transmission (10, 13, 15, 18, 19, 24). The resurgence of TB in industrialized countries in the past decade has resulted in an increasing number of specimens and cultures being tested in laboratories, thereby enhancing the potential of accidental exposure for laboratory staff.

Stringent safety precautions must be followed for laboratory work with *M*. *tuberculosis* (6, 14). There remains one part of the routine laboratory process, however, where the hazard for potential exposure has not been addressed—unstained smears. Specimen and culture manipulations for mycobacteriological analyses, including the preparation of smears, are carried out within a biosafety cabinet (BSC). The smears are usually then heat fixed by passage of the slides through the flame of a gas burner or by placement on a hot plate. After the smears are fixed, they are removed from the BSC to a staining sink or they may be stored, transported to a reference laboratory, or used in proficiency testing panels.

Several studies have shown that heat-fixed smear material, whether fixed by flaming or for 2 h at 65°C on a hot surface, still contains viable bacilli (1, 4; L. R. B. Giacomelli, S. R. Sespede, A. M. W. Barreto, and C. L. Cardoso, Abstr. Clin. Microbiol., abstr. C-129, p. 131, 1999). Our data from this study confirm that *M*. *tuberculosis* is still viable after flame fixing of smear material. Additional problems with heat fixing are that the use of a flame inside a BSC is not recommended and that 2 h of fixing on a hot plate is cumbersome and time-consuming when large numbers of slides must be fixed.

When slides containing viable *M*. *tuberculosis* smear material are removed from a BSC, laboratory staff can be exposed to infective material if slides are broken, thereby possibly generating aerosols or skin penetration, or the smear material may flake off slides, thus potentially infecting the worker and contaminating the laboratory environment. Staining methods used for acid-fast bacilli (AFB), whether fluorochrome or carbol fuchsin based, are known to kill mycobacteria. However, staining is done over a sink outside the BSC, necessitating the prior removal of unstained smears from the cabinet.

The purpose of this study was to determine a rapid method which would inactivate as well as fix smear preparations of *M*. *tuberculosis* within the BSC while still retaining good staining performance. Solutions of 70% ethanol and 1, 3, and 5% phenol in 70% ethanol as well as heat flaming were used to fix smears of sputum concentrates containing high numbers of AFB as well as smears of *M*. *tuberculosis* cultures. After the smear material was fixed, it was tested for viability by using the BACTEC 460 culture system (Becton Dickinson, Sparks, Md.). Fixed smears were also stained to check the quantity of AFB present and the quality of the stained smears.

Preliminary reagent fixing tests were carried out in parallel at two separate laboratories: the Laboratories Branch, Ontario Ministry of Health and Long-Term Care, Toronto, Ontario, Canada, and the Florida Department of Health, Bureau of Laboratories, Jacksonville. After the results of these tests were examined, additional tests to confirm the preliminary finding that 5% phenol in ethanol was the optimal reagent, as well as heat fixing tests, were performed at the Ontario laboratory.

#### **MATERIALS AND METHODS**

Unused microscope slides were cleaned by soaking in 70% ethanol for 30 min and drying before use. All test procedures, including preparing smear material, making smears, and air drying, fixing, and inoculating samples into BACTEC (BT) vials, were performed inside a BSC. All smear materials were tested for viability both before and after fixing and for staining quality after fixing.

**Preliminary reagent fixing tests.** Air-dried smears made from *M*. *tuberculosis*spiked sputum concentrates and from cultures of *M*. *tuberculosis* growing on Lowenstein-Jensen (LJ) slants were fixed in all of the test reagents for 5 and 10 min. The following reagents were tested: 70% ethanol and 1, 3, and 5% phenol in 70% ethanol.

These tests were performed in parallel at two laboratories.

<sup>\*</sup> Corresponding author. Mailing address: Laboratories Branch, Ministry of Health and Long-Term Care, 81 Resources Rd., Toronto, Ontario, Canada M9P 3T1. Phone: (416) 235-5993. Fax: (416) 235- 6013. E-mail: pam.chedore@moh.gov.on.ca.

For each smear material, fixing reagent, and fixing time, four identically prepared smears were used. Smears 1 and 2 were fixed and tested for viability, smear 3 was fixed and stained, and smear 4 was left unfixed and tested for viability as a growth control (Fig. 1).



FIG. 1. Scheme for the treatment of smear material samples.

**Heat (flame) fixing test.** Twelve smears each from *M*. *tuberculosis*-spiked sputum concentrates and from *M*. *tuberculosis* cultures on LJ slants were prepared and air dried. Eleven smears from each smear material were heat fixed by passage three times through the flame of a gas burner and then allowed to cool. Ten smears from each smear material were then tested for viability, and the remaining smear was stained. The remaining two unfixed smears were tested for viability as growth controls.

**Confirmation tests.** Three smears each from 22 AFB-positive  $(3+)$  or  $4+$ , where  $3+$  is 1 to 9 AFB per  $\times$ 100 field and  $4+$  is more than 9 AFB per  $\times$ 100 field) clinical sputum concentrates and from 10 isolates of *M*. *tuberculosis* growing both on LJ slants and in Mycobacterium Growth Indicator tubes (MGIT) (Becton Dickinson) were prepared and air dried. Smear 1 from each set was fixed and tested for viability, smear 2 was fixed and stained, and smear 3 was left unfixed and tested for viability as a growth control.

All confirmation test smears were fixed for 5 min in 5% phenol in ethanol only. **Preparation of** *M***.** *tuberculosis***-spiked sputum concentrates.** A suspension of *M*. *tuberculosis* equivalent to a McFarland no. 1 standard was prepared in 5 ml of sterile saline. Three milliliters of this suspension was centrifuged at  $7,600 \times g$  for 15 min, and the supernatant was discarded. The cell button was transferred to a tube containing 3 ml of decontaminated, AFB-negative sputum concentrate material and vortexed well.

**Preparation of smears.** Smears from sputum concentrates were prepared by placing  $20$ - $\mu$ l amounts of material on slides and then air drying the slides.

Smears from LJ cultures were prepared by emulsifying a loopful of culture in  $20 \mu l$  of sterile saline on a slide and air drying the slides.

Smears from MGIT cultures were prepared by placing 20-µl aliquots of the growth sediment from the tubes on slides and then air drying the slides.

**Fixing methods. (i) Reagent tests.** Wash bottles containing 70% ethanol and 1, 3, and 5% phenol in 70% ethanol were prepared. Smears were prepared, air dried, and placed on a rack over a pan inside the BSC. Each of the fixing solutions was applied for 5 and 10 min by flooding the smears with reagent from the wash bottle. The smears for viability testing were then washed thoroughly for 2 min in distilled water to remove the fixing reagent. The smears for staining were stained directly after fixing, without removal of the reagent.

**(ii) Heat fixing tests.** Air-dried smears were heat fixed by passage three times through the flame of a gas burner and then allowed to cool.

**Viability tests.** Smear material from the fixed and washed slides was scraped into tubes of 0.5 ml of sterile saline by using sterile swabs. The swabs were squeezed against the sides of the tubes to remove the smear material. This material was then inoculated into BT vials supplemented with 0.1 ml of PANTA (Becton Dickinson). The BT vials were incubated at 37°C and monitored for growth twice weekly for 8 weeks by using the BACTEC 460 system. Vials from the confirmation tests were further incubated and tested for growth at 12 weeks. A smear was made from any vial showing growth when the growth index reached 100. A blood agar plate was inoculated with 0.1 ml of culture from any vial showing growth and was incubated for 48 h at 37°C to check for contamination.





*<sup>a</sup>* For each sample, reagent, and time, four replicates were used. Results from two laboratories are combined.

Smears from positive BT cultures were stained by the Kinyoun method and examined for AFB.

**Growth controls.** One smear from each test set was left unfixed and inoculated into a BT vial, as in the protocol used for the viability tests, as a growth control.

**Staining controls.** One smear from each test set was fixed and stained to assess the quantity of AFB and the quality of the stained smears. Smears from sputum concentrates were stained by the auramine-rhodamine method, and smears from cultures were stained by the Kinyoun method.

#### **RESULTS**

**Preliminary reagent fixing tests.** After being fixed in 70% ethanol, two of four *M*. *tuberculosis*-spiked concentrate smears and one of four *M*. *tuberculosis* LJ culture smears remained viable after 5 min of fixing (Table 1). One of four *M*. *tuberculosis* LJ culture smears was viable after 10 min of fixing.

After being fixed in 1% phenol in ethanol, one of four *M*. *tuberculosis*-spiked concentrate smears was viable after 5 min of fixing and one of four *M*. *tuberculosis* LJ culture smears was viable after 10 min of fixing (Table 1).

After being fixed in 3% phenol in ethanol, two of four *M*. *tuberculosis* LJ culture smears were viable after both 5 and 10 min of fixing (Table 1).

After being fixed in 5% phenol in ethanol, all smears tested were nonviable after 5 and 10 min of fixing (Table 1).

**Flame fixing tests.** Materials from flame-fixed smears (10 each for *M*. *tuberculosis*-spiked concentrate material and *M*. *tuberculosis* LJ culture material) all remained viable after heat fixing.

**Confirmation tests.** After being fixed in 5% phenol in ethanol for 5 min, all smears tested (AFB-positive sputum concentrates  $[n = 22]$ , *M. tuberculosis* from LJ slants  $[n = 10]$ , and *M. tuberculosis* from MGIT cultures  $[n = 10]$  were nonviable.

**Controls. (i) Growth controls.** Unfixed growth controls from all tests were viable, indicated by a rising growth index in BT cultures. Smears from these cultures showed AFB, with cording in *M*. *tuberculosis* cultures, and tests for contamination were negative.

**(ii) Staining controls.** All smears showed good staining and the presence of  $3+$  or  $4+$  AFB.

**Viability tests.** All BT vials from viability tests showing growth had AFB-positive smears, with *M*. *tuberculosis* cultures demonstrating typical cording. Sterility plates showed no growth of contaminants at 48 h. The 22 specimen concentrates used in confirmation tests yielded cultures of *M*. *tuberculosis* (13), *M*. *avium* complex (4), *M*. *kansasii* (1), and *M*. *xenopi* (4).

## **DISCUSSION**

The incidence of TB infections in laboratory workers is estimated to be three to nine times greater than that in the general population (8, 13, 20, 22). In the past 20 years, 44% of all reported laboratory-acquired bacterial infections have been due to *M*. *tuberculosis* (7). Because of the low infective dose of *M*. *tuberculosis* for humans (fewer than 10 bacilli represent a 50% infective dose [9, 11, 23]), all clinical specimens from patients with possible TB must be considered potentially infectious. The presence of multidrug-resistant strains of *M*. *tuberculosis* now isolated in laboratories and the increased workload of specimens and cultures being processed in large laboratories have enhanced the potential hazard of TB infections for laboratory workers.

The most common route of transmission of *M*. *tuberculosis* is via aerosols, which may be generated at any stage of the laboratory processing of specimens and cultures as well as from work with infected animals (2, 17, 25, 26). Cutaneous injury infections with *M*. *tuberculosis* have also been reported (16, 24). There are no documented reports of laboratory-acquired TB infections that can be directly attributed to the manipulation of unstained smears; however, in most instances the actual source of exposure for laboratory-acquired TB infections remains unknown (7).

Mycobacteriology laboratory staff should carry out a risk assessment of all stages of their laboratory operations (12, 23), recognizing that *M*. *tuberculosis* is classified as a biosafety level 3 risk agent (6, 14). The preparation of smear material on microscope slides from specimens and cultures, when carried out within a certified BSC and with biosafety level 3 operational precautions (14), should not present a hazard. The removal of smears from the BSC, if the material contains viable bacilli, carries the possible risk of aerosol transmission or cutaneous infection if the slides are broken or if material flakes off the slides.

The traditional method for fixing AFB smear material is heating. Dried material on slides may be passed several times through the flame of a gas burner, or slides may be placed on a heat block. Several studies, as well as our data, have shown that heat fixing does not kill *M*. *tuberculosis* (1, 4; Giacomelli et al., Abstr. Clin. Microbiol.).

The resistance of mycobacteria to disinfectants is considered to be due to the high lipid content of their complex cell wall (3, 5, 21). Ethanol has been shown to be tuberculocidal with sufficient contact time when used to treat suspensions of *M*. *tuberculosis*, but it is less effective in the presence of organic material, such as sputum (3, 26). Alcohols are also effective fixing agents. Phenol is a known tuberculocidal agent, even in the presence of concentrated organic material, such as sputum (5, 21, 26). In this study, we tested 70% ethanol as well as three concentrations of phenol in 70% ethanol in order to determine an effective fixing agent that would also rapidly inactivate *M*. *tuberculosis* and that could be applied within the confines of a BSC. Smears containing high numbers of *M*. *tuberculosis* and other AFB in sputum concentrates, as well as smears prepared from actively growing *M*. *tuberculosis* obtained from solid and

liquid culture media, were investigated. The methods replicated routine smear preparation work as it is performed in most mycobacteriology laboratories.

Our tests verified that heat fixing smears by passing them through a gas flame does not inactivate *M*. *tuberculosis* bacilli. Preliminary fixing test results showed that phenol-ethanol solutions were more successful in inactivating *M*. *tuberculosis* smear material. While some smears were inactivated by the lower phenol concentrations, optimal results were obtained with a solution of 5% phenol in ethanol. Smears made from a solid culture medium, such as LJ slants, potentially contain more biomass of *M*. *tuberculosis* than do smears made from specimen concentrates. This fact would explain the higher concentration of phenol in ethanol required to inactivate these smears (Table 1). Smears made from concentrated sputum contain a high organic load and therefore require an agent such as phenol for successful inactivation. The confirmation tests showed that the application of 5% phenol in alcohol for 5 min both fixed and inactivated all the smear material tested without affecting subsequent staining quality. A total of 50 smears from both AFB-positive sputum concentrates and *M*. *tuberculosis* cultures were successfully inactivated by this method during our tests.

We therefore recommend that all smears that may contain *M*. *tuberculosis* be treated with 5% phenol in ethanol for 5 min within a BSC as a rapid and effective fixing and inactivating method. The fixing solution can be applied to air-dried slides placed on a rack over a pan within the cabinet. Smears can then be safely removed from the BSC for staining, storage, or transportation.

When agents, such as *M*. *tuberculosis*, that are infectious for humans are processed within laboratories, they present a risk to workers, coworkers, and the community. The recognition of potential hazards by laboratory risk assessments and the institution of protocols to minimize or eliminate the potential for exposure to the agents are effective ways to avoid laboratoryacquired infections.

### **REFERENCES**

- 1. **Allen, B. W.** 1981. Survival of tubercle bacilli in heat-fixed sputum smears. J. Clin. Pathol. **34:**719–722.
- 2. **Barenfanger, J.** 1993. Making your lab safe against multi-drug-resistant *Mycobacterium tuberculosis*. Clin. Microbiol. Newsl. **15:**76–80.
- 3. **Best, M., S. A. Sattar, V. S. Springthorpe, and M. E. Kennedy.** 1990. Efficacies of selected disinfectants against *Mycobacterium tuberculosis*. J. Clin. Microbiol. **28:**2234–2239.
- 4. **Blair, E. B., W. W. Bretherton, and A. H. Tull.** 1972. A method to render unstained mycobacterial smears safe for storage or shipment. Appl. Microbiol. **23:**826.
- 5. **Block, S. S.** 1991. Disinfection, sterilization and preservation, 4th ed. Lea & Febiger, Publishers, Philadelphia, Pa.
- 6. **Centers for Disease Control and Prevention and National Institutes of Health.** 1999. Biosafety in microbiological and biomedical laboratories, 4th ed. U.S. Department of Health and Human Services, Washington, D.C.
- 7. **Harding, A., and K. Brandt Byers.** 2000. Epidemiology of laboratory-associated infections, p. 35–54. *In* D. O. Fleming and D. L. Hunt (ed.), Biological safety: principles and practices, 3rd ed. ASM Press, Washington, D.C.
- 8. **Harrington, J. M., and H. S. Shannon.** 1976. Incidence of tuberculosis, hepatitis, brucellosis and shigellosis in British medical laboratory workers. Br. Med. J. **1:**759–762.
- 9. **Health Canada.** 1996. Guidelines for preventing the transmission of tuberculosis in Canadian Health Care Facilities and other institutional settings. Can. Commun. Dis. Rep. **22**(Suppl. 1)**:**1–50.
- 10. **Kao, A. S., D. A. Ashford, M. M. McNeil, N. G. Warren, and R. C. Good.** 1997. Descriptive profile of tuberculin skin testing programs and laboratoryacquired tuberculosis infections in public health laboratories. J. Clin. Microbiol. **35:**1847–1851.
- 11. **Knudsen, R. C.** 1998. Risk assessment for biological agents in the laboratory. J. Am. Biol. Safety Assoc. **3:**99–104.
- 12. **Knudsen, R. C.** 1999. Risk assessment for working with infectious agents in the biological laboratory, p. 1–10. *In* J. Y. Richmond (ed.), Anthology of biosafety. III. Application of principles. American Biological Safety Association, Mundelein, Ill.
- 13. **Kubica, G. P.** 1990. Your tuberculosis laboratory: are you really safe from infection? Clin. Microbiol. Newsl. **12**:85–87.
- 14. **Laboratory Centre for Disease Control.** 1996. Laboratory biosafety guidelines, 2nd ed. Health Canada, Health Protection Branch, Ottawa, Ontario, Canada.
- 15. **Menzies, D., A. Fanning, L. Yuan, and M. Fitzgerald.** 1995. Tuberculosis among health care workers. N. Engl. J. Med. **332:**92–98.
- 16. **Peerbooms, P. G. H., G. J. J. van Doornum, H. van Deutekom, R. A. Coutinho, and D. van Soolingen.** 1995. Laboratory-acquired tuberculosis. Lancet **345:**1311–1312.
- 17. **Pike, R. M.** 1976. Laboratory-associated infections: summary and analysis of 3291 cases. Health Lab. Sci. **13:**105–114.
- 18. **Pike, R. M.** 1978. Past and present hazards of working with infectious agents. Arch. Pathol. Lab. Med. **102:**333–336.
- 19. **Pike, R. M.** 1979. Laboratory-associated infections: incidence, fatalities, causes and prevention. Annu. Rev. Microbiol. **33:**41–66.
- 20. **Reid, D. D.** 1957. Incidence of tuberculosis among workers in medical laboratories. Br. Med. J. **2:**10–14.
- 21. **Rutala, W. A., E. C. Cole, N. S. Wannamaker, and D. J. Weber.** 1991. Inactivation of *Mycobacterium tuberculosis* and *Mycobacterium bovis* by 14 hospital disinfectants. Am. J. Med. **91:**267S-271S.
- 22. **Saint-Paul, M., Y. Delplace, C. Tufel, G. B. Cabasson, and A. Cavieneaux.** 1972. Tuberculoses professionelles dan les laboratoires de bacteriologie. Arch. Mal. Prof. Med. Trav. **33:**305–309.
- 23. **Sewell, D. L.** 1995. Laboratory-associated infections and biosafety. Clin. Microbiol. Rev. **8:**389–405.
- 24. **Sharma, V. K., B. Kumar, B. D. Radotra, and S. Kaur.** 1990. Cutaneous inoculation tuberculosis in laboratory personnel. Int. J. Dermatol. **29:**293– 294.
- 25. **Shireman, P. K.** 1992. Endometrial tuberculosis acquired by a health care worker in a clinical laboratory. Arch. Pathol. Lab. Med. **116:**521–523.
- 26. **Voss, A.** 1999. Prevention and control of laboratory-acquired infections, p. 165–166. *In* P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 7th ed. American Society for Microbiology, Washington, D.C.